What Is 5-Amino-1MQ?
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule inhibitor of nicotinamide N-methyltransferase, an enzyme usually shortened to NNMT. It is often listed alongside research peptides, but strictly speaking it is not a peptide at all: it is a compact, membrane-permeable quinolinium compound with a molecular weight of roughly 159 g/mol for the active cation, a fraction of the size of even the shortest peptides. That small size is part of what made it interesting to the researchers who designed it, because it can cross cell membranes and reach NNMT inside the cell.
Interest in "5-Amino-1MQ Australia" has grown as metabolic research has moved beyond appetite and incretin pathways towards the enzymes that control how cells handle energy and methyl groups. This guide explains what NNMT does, what the published preclinical studies on 5-Amino-1MQ report, and how the compound is handled in the lab. Optic Labs supplies research-grade 5-Amino-1MQ 10mg in Australia, third-party HPLC tested, with a Certificate of Analysis for each batch.
Understanding NNMT: The Enzyme 5-Amino-1MQ Targets
Nicotinamide N-methyltransferase transfers a methyl group from S-adenosylmethionine (SAM) to nicotinamide, a form of vitamin B3. The products are 1-methylnicotinamide (MNA) and S-adenosylhomocysteine (SAH). NNMT is expressed most strongly in the liver and in adipose (fat) tissue, and it sits at the junction of two pathways that matter a great deal in metabolic research:
- The NAD+ salvage pathway. Nicotinamide is the main recycled precursor for NAD+, the coenzyme at the centre of cellular energy metabolism and sirtuin signalling. When NNMT methylates nicotinamide, that molecule is diverted away from NAD+ recycling.
- The methionine cycle. Every methylation by NNMT consumes SAM, the cell's universal methyl donor. High NNMT activity can therefore act as a "methyl sink" that influences SAM availability for other reactions, including epigenetic methylation.
For researchers already working with NAD+, this is why NNMT inhibition attracts attention: it targets the consumption side of the NAD+ equation rather than adding precursor. Our NAD+ research guide covers the NAD+ side of that story, and NAD+ 1000mg is available for parallel work.
The 2014 study that put NNMT on the map
NNMT moved from a niche enzyme to a metabolic research target after a 2014 paper in Nature by Kraus and colleagues. Using antisense oligonucleotides to knock down NNMT expression in the fat and liver of mice fed a high-fat diet, the researchers reported that the animals were protected against diet-induced obesity. They linked this to higher energy expenditure in adipose tissue, accompanied by increased SAM and NAD+ levels and changes in histone methylation. The study also reported that NNMT expression was raised in the fat tissue of obese and diabetic mice. That work set up the question 5-Amino-1MQ was designed to answer: could a small-molecule drug reproduce the effect of genetic knockdown?
What the Preclinical Research on 5-Amino-1MQ Reports
Most of the published 5-Amino-1MQ literature comes from a research group at the University of Texas Medical Branch led by Harshini Neelakantan and Stanley Watowich. All of the studies below are in cell or animal models. 5-Amino-1MQ has not been evaluated in published human trials.
Diet-induced obesity in mice (2018)
In a 2018 paper in Biochemical Pharmacology, the group described a series of selective, membrane-permeable quinolinium NNMT inhibitors, with 5-amino-1MQ among the most promising. In cultured adipocytes, the inhibitor reduced intracellular MNA, raised NAD+ and SAM levels, and suppressed lipogenesis. In mice with diet-induced obesity, systemic treatment was reported to reduce body weight and white adipose mass, shrink adipocyte size and lower plasma total cholesterol, without a significant change in food intake. The finding that food intake was unchanged is a notable contrast with appetite-focused compounds.
Aged muscle stem cells (2019)
A follow-up study in 2019, also in Biochemical Pharmacology, examined NNMT inhibition in aged mice. The authors reported that the inhibitor activated senescent muscle stem cells (satellite cells) and improved the regenerative capacity of aged skeletal muscle after injury, with increases in muscle fibre size and contractile force in the treated animals. This study broadened interest in NNMT from fat metabolism into ageing and muscle research.
Metabolic dysfunction and liver outcomes (2024)
A 2024 study by Babula and colleagues in Diabetes, Obesity and Metabolism treated diet-induced obese mice once daily for 28 days. The researchers reported dose-related reductions in body weight and fat mass gain, improved glucose tolerance and insulin sensitivity, and lower fasting insulin. In the liver, treated animals showed less fat accumulation, less macrophage infiltration and lower triglycerides, and circulating ALT and AST normalised. The paper also characterised pharmacokinetics after intravenous, oral and subcutaneous administration, reporting that subcutaneous dosing produced high systemic exposure and distribution to adipose tissue, muscle and liver.
How 5-Amino-1MQ Fits Into Metabolic Research
Metabolic research in Australia now spans several very different mechanisms, and 5-Amino-1MQ occupies its own niche:
- Incretin-pathway compounds such as Retatrutide act on GLP-1, GIP and glucagon receptors and are studied heavily for appetite and energy-balance effects. See our Retatrutide Australia guide.
- Growth hormone fragments such as AOD-9604 are studied for effects on lipolysis. Our AOD-9604 research guide covers that literature.
- Mitochondrial peptides such as MOTS-c are studied for effects on AMPK signalling and insulin sensitivity.
- NNMT inhibitors such as 5-Amino-1MQ act on an intracellular enzyme that links NAD+ recycling to methyl-group balance, with preclinical data pointing to changes in adipocyte energy handling rather than appetite.
This difference in mechanism is why some research designs look at NNMT inhibition alongside, rather than instead of, other metabolic compounds. Our overview of how compounds are combined in research discusses the general logic of multi-pathway study design.
Handling, Reconstitution and Storage
Research-grade 5-Amino-1MQ is supplied as a lyophilised powder in a sealed vial. As with peptides, sealed vials are normally kept cool, dry and protected from light, with freezer storage for the long term. Once dissolved, the compound should be refrigerated at 2–8°C and used within the time frame specified in the lab's protocol. Reconstitution is commonly done with bacteriostatic water, and our free peptide calculator converts vial size and diluent volume into concentration. For general guidance on temperature, light and freeze-thaw cycles, see our storage guide.
Sourcing 5-Amino-1MQ in Australia
5-Amino-1MQ is not an approved therapeutic good in Australia and is supplied strictly for laboratory and research use. Our guide to Australian regulation and TGA compliance explains what research-use-only status means in practice.
Because 5-Amino-1MQ is a small molecule rather than a peptide, identity testing matters just as much as purity. A batch Certificate of Analysis should show HPLC purity and mass spectrometry confirming the expected molecular mass. Optic Labs publishes batch results in our COA library, and every vial of 5-Amino-1MQ 10mg is third-party tested at 99%+ purity and shipped from Sydney Australia-wide.
Frequently Asked Questions
What is 5-Amino-1MQ?
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT). It was developed by researchers at the University of Texas Medical Branch and has been studied in cell and mouse models of obesity, metabolic dysfunction and muscle ageing.
Is 5-Amino-1MQ a peptide?
No. Although it is often sold by research peptide suppliers, 5-Amino-1MQ is a small quinolinium molecule, not a chain of amino acids. Its small size and membrane permeability allow it to reach NNMT inside cells.
What does NNMT do?
NNMT uses S-adenosylmethionine (SAM) to methylate nicotinamide, producing 1-methylnicotinamide. This diverts nicotinamide away from NAD+ recycling and consumes methyl groups, so NNMT activity influences both NAD+ and SAM levels in tissues such as fat and liver.
What do studies on 5-Amino-1MQ show?
Published mouse studies report that NNMT inhibition with 5-Amino-1MQ reduced weight and fat mass gain in diet-induced obesity without a significant change in food intake, improved markers of glucose handling and liver fat, and improved regeneration in aged muscle. These are preclinical findings, and no human trial results have been published.
How is 5-Amino-1MQ related to NAD+?
NNMT consumes nicotinamide, the main recycled precursor of NAD+. Inhibiting NNMT is studied as a way to preserve nicotinamide for NAD+ salvage, and cell studies of 5-Amino-1MQ reported higher intracellular NAD+ levels.
Is 5-Amino-1MQ approved in Australia?
No. It is not an approved medicine in Australia or elsewhere and is supplied for laboratory research use only.
This article is for educational and research purposes only. Optic Labs products are intended for research use only and are not for human consumption. Always consult a qualified healthcare professional before considering any compounds.